
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid is supported by a strong clinical and regulatory setup for D-PLEX100, with SHIELD II showing about a 60% reduction in incisional surgical-site infections and the NDA already under Priority Review for the November 28, 2026 PDUFA. The company’s partnership with Azurity materially de-risks commercialization by funding launch and label-expansion work while still leaving PolyPid with tiered mid-teens to mid-20s royalties, manufacturing revenue, and over $290M of potential milestones after the $30M already received. Fundamentally, the balance sheet also improved, as 3Q26 net loss narrowed to $5.8M and pro forma cash rose to about $30.5M, giving management runway into 2028 while broader abdominal surgery, Europe, and PD01B add longer-term upside.
Bears say
PolyPid is viewed negatively because its valuation is tied almost entirely to D-PLEX100, which is still under FDA review with a November 28, 2026 PDUFA date and remains exposed to a CRL, extra study request, or restrictive label that could narrow the market. Even if approved, commercialization depends on Azurity’s execution, hospital-by-hospital formulary adoption, and uncertain reimbursement, including a possible denial of FY2028 NTAP that could leave hospitals absorbing full product cost and keep penetration in the low single digits through 2028. The company also faces manufacturing and financing risk, as FDA inspection or supply issues could delay launch while slower uptake could force dilutive financing, and bears note a modest upfront deal, limited near-term revenue, and a June 2025 warrant overhang.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PolyPid (PYPD) Forecast
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares